FibroGen Inc (FGEN)
1.165
-0.10
(-7.54%)
USD |
NASDAQ |
Apr 18, 16:00
1.165
0.00 (0.00%)
After-Hours: 20:00
FibroGen Cash from Operations (TTM): -315.02M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -315.02M |
September 30, 2023 | -349.21M |
June 30, 2023 | -316.56M |
March 31, 2023 | -239.05M |
December 31, 2022 | -145.93M |
September 30, 2022 | -148.38M |
June 30, 2022 | -52.24M |
March 31, 2022 | -45.72M |
December 31, 2021 | -82.23M |
September 30, 2021 | -34.50M |
June 30, 2021 | -80.10M |
March 31, 2021 | 96.10M |
December 31, 2020 | 81.60M |
September 30, 2020 | 43.78M |
June 30, 2020 | 17.65M |
March 31, 2020 | -160.67M |
December 31, 2019 | -78.70M |
September 30, 2019 | -51.12M |
June 30, 2019 | -15.39M |
Date | Value |
---|---|
March 31, 2019 | -21.70M |
December 31, 2018 | -76.14M |
September 30, 2018 | -59.86M |
June 30, 2018 | -86.55M |
March 31, 2018 | -71.34M |
December 31, 2017 | -66.51M |
September 30, 2017 | -83.87M |
June 30, 2017 | -67.20M |
March 31, 2017 | -2.769M |
December 31, 2016 | 7.108M |
September 30, 2016 | -13.65M |
June 30, 2016 | -50.01M |
March 31, 2016 | 6.361M |
December 31, 2015 | -18.57M |
September 30, 2015 | -3.033M |
June 30, 2015 | 4.033M |
March 31, 2015 | -4.255M |
December 31, 2014 | 22.41M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-349.21M
Minimum
Sep 2023
96.10M
Maximum
Mar 2021
-98.72M
Average
-78.70M
Median
Dec 2019
Cash from Operations (TTM) Benchmarks
Emergent BioSolutions Inc | -206.30M |
Geron Corp | -167.74M |
Regulus Therapeutics Inc | -26.77M |
Fate Therapeutics Inc | -132.26M |
Aldeyra Therapeutics Inc | -30.33M |